Marisa Wexler, MS,  senior science writer—

Treatment with Aubagio (teriflunomide) may significantly reduce the risk of relapse in children with multiple sclerosis (MS), according to a new analysis of the TERIKIDS clinical trial that took into account data from adult trials. Results were in the paper “Reinterpreting Clinical Trials in Children With…

Some prodromal symptoms of multiple sclerosis (MS) — symptoms that are evident before the disease begins in earnest — could help to predict the course of MS, a new study proposes. In particular, its researchers suggest that MS patients with prodromal depression are more likely to be diagnosed…

Levels of certain inflammatory proteins in the cerebrospinal fluid, the liquid around the brain and spinal cord, may help predict the risk of relapse activity for individuals with early multiple sclerosis (MS), a new study found. High levels of three such proteins were predictive of a greater risk of…

An MRI technique called quantitative susceptibility mapping (QSM) can be used to accurately identify remyelinated brain lesions in people with multiple sclerosis (MS), a research team has discovered. Remyelinated lesions are those in which the myelin sheath — the protective coating around nerve fibers that is progressively lost…

The safety and efficacy of the approved multiple sclerosis (MS) therapy Mavenclad (cladribine) in a real-world group of patients were similar to what had been demonstrated in clinical trials, a new study reports. Among 243 people with relapsing-remitting multiple sclerosis (RRMS), more than 60% showed no…

Long-term treatment with Zeposia (ozanimod) stabilizes or even improves cognitive function in adults with relapsing forms of multiple sclerosis (MS), particularly among those with greater brain volumes. That’s according to five years of data from the completed SUNBEAM Phase 3 clinical trial (NCT02294058) and the ongoing…

People with relapsing forms of multiple sclerosis (MS) who were continuously on Kesimpta (ofatumumab) for up to four years were about four times more likely to have no evidence of disease activity than those initially on Aubagio (teriflunomide), according to updated data from the ASCLEPIOS and ALITHIOS…

Proteins called tenascins block the regeneration of myelin by modulating the activity of oligodendrocytes, myelin-making cells of the central nervous system, a study in mouse models indicates. “Our research results open up new therapeutic approaches for the treatment of demyelinating diseases such as multiple sclerosis,” Juliane Bauch, a researcher at Ruhr-University…

Unusual growth in an immune cell class called myeloid cells is evident in the bone marrow of people with multiple sclerosis (MS), and these cells likely contribute to the inflammation that drives the disease, according to a new study. Experiments in mice suggest that myelin-reactive T-cells can migrate to the bone…

Cionic‘s leg-worn Neural Sleeve, recently authorized in the U.S. to aid walking in people with multiple sclerosis (MS) and other conditions that impair mobility, reduced foot drop in a small clinical trial. Patients in the trial also reported marked reductions in pain and mental health problems, according to…

Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosis (RRMS), data from the Phase 2 EMPhASIS clinical trial shows. Top-line results from EMPhASIS were reported by the therapy’s developer Immunic Therapeutics in 2020. Researchers at…

Treatment with foralumab nasal spray resulted in marked clinical improvements after three months in the second secondary progressive multiple sclerosis (SPMS) patient treated under a single-patient access program. The findings were generally consistent with those seen in the first SPMS patient and supported a decision by the U.S. Food…

The overall risk of death is about 75% higher for people with multiple sclerosis (MS) than in the general population, according to a new study. “The association was independent of demographic, socioeconomic variables, lifestyle factors, baseline diabetes, cardiovascular disease, chronic respiratory disease, and cancer status,” researchers wrote. The study,…

A medication currently approved to treat certain kinds of cancer, called topotecan, could be repurposed for treating neuroinflammatory conditions such as multiple sclerosis (MS) because it reduces the inflammatory activity of immune cells called microglia. That’s according to the study, “Myeloid cell-specific topoisomerase 1 inhibition using DNA origami…

More than half of the people with multiple sclerosis (MS) treated with Aubagio (teriflunomide) showed no evidence of disease activity after two years on treatment, according to a study in Italy. The study, “Evolution of teriflunomide use in multiple sclerosis: A real-world experience,” was published in the Journal of…

The U.S. Food and Drug Administration (FDA) is extending by three months its review of ublituximab, an experimental anti-CD20 antibody being developed by TG Therapeutics for relapsing forms of multiple sclerosis (MS). The FDA had agreed to review the company’s application requesting ublituximab’s approval late last year, and…

A new scoring system might more precisely evaluate disease development, severity, and treatment response in a commonly used mouse model of multiple sclerosis (MS) known as the experimental autoimmune encephalomyelitis or EAE model, scientists report. This scoring system, called “I AM D EAE,” was described in the study, “…

Among multiple sclerosis (MS) patients starting on Lemtrada (alemtuzumab), an early decrease in the leakiness of the blood-brain barrier (BBB) is associated with a lower likelihood of disease activity after two years, according to a new study. The blood-brain barrier is a cellular divisor that regulates which substances…

Treatment with Ponvory (ponesimod) significantly reduces the risk of worsening disability or new relapses for people with relapsing forms of multiple sclerosis (MS) compared with a placebo, according to a new analysis funded by the therapy’s maker Janssen. The study, “Comparative Efficacy of Relapsing Multiple Sclerosis Therapies:…

People with multiple sclerosis (MS) are more likely to have lesions in three regions of the brain — the anterior temporal horn, periventricular region, and cerebellar hemisphere — compared with people with other inflammatory brain diseases, a study reports. Looking for lesions in these parts of the brain may…

ABX-002, an experimental treatment for multiple sclerosis (MS) being developed by Autobahn Therapeutics, promoted the restoration of the myelin sheath in preclinical models of the disease, new data show. The research, which specifically tested an analog of ABX-002 called LL-341070, will be presented by Autobahn’s academic collaborators at…

Among people with relapsing-remitting multiple sclerosis (RRMS), those who are married and have more formal education are more likely to take treatments as recommended, according to a new study from Iran. The study, “Effects of Disease-Modifying Treatments discontinuation in patients with Relapsing-Remitting Multiple Sclerosis: A 5…

Many people newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) experience substantial “hidden disabilities,” such as depression or fatigue, a study highlights. Findings indicate that treatment with disease-modifying therapies generally does not affect the severity of these problems, at least in the short term. “Considering the substantial impact that hidden…

Among multiple sclerosis (MS) patients on rituximab, higher B-cell counts are predictive of a better antibody-based response to a vaccine for COVID-19, according to a new Swedish study. “In our study, the B-cell level in patients given Rituximab was the only factor that influenced the ability to form antibodies…

The experimental therapy XPro1595 was found to promote remyelination — the repair of the myelin sheath — in a mouse model of myelin loss, new data show. Myelin, the fatty covering that helps nerve fibers send electrical signals, is damaged by the immune system in …

Eating a ketogenic diet — one low in carbohydrates and high in fats — led to markedly less fatigue and depression for people with relapsing-remitting multiple sclerosis (RRMS) in a small clinical trial that was designed to assess the tolerability of the dietary intervention. Measures of disability and quality…

Researchers have identified four new brain proteins that are targeted by inflammatory T-cells in multiple sclerosis (MS), which could aid in the development of more specific and safer treatments for people with the condition. The study, “Identification of four novel T cell autoantigens and personal autoreactive profiles in…

More than half of Canadians with multiple sclerosis (MS) report using cannabis to help manage their symptoms, according to a new study. The study, “Medical cannabis use in Canadians with multiple sclerosis,” was published in Multiple Sclerosis and Related Disorders. Humans have used the cannabis plant for millennia,…

Tysabri (natalizumab) given every six weeks was found to be similarly effective as the standard four-week dosing schedule at stopping nervous system damage in people with relapsing-remitting multiple sclerosis (RRMS). That’s according to the full results of the Phase 3b NOVA clinical trial, which compared Tysabri dosing schedules…

The National Institute for Health and Care Evidence (NICE) in England has issued a briefing on the use of Icometrix‘s icobrain system to assess disease activity in people with multiple sclerosis (MS) based on MRI scans. The NICE statement was in the form of a medtech innovation briefing, or…